

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/10, 15/64, C12Q 1/68	A1	(11) International Publication Number: WO 95/29994 (43) International Publication Date: 9 November 1995 (09.11.95)
(21) International Application Number: PCT/US95/05389 (22) International Filing Date: 24 April 1995 (24.04.95) (30) Priority Data: 234,981 28 April 1994 (28.04.94) US (71) Applicants: MICHIGAN STATE UNIVERSITY [US/US]; 238 Administration Building, East Lansing, MI 48824 (US). THE GOVERNMENT OF THE UNITED STATES OF AMERICA, re [US/US]; presented by THE SECRETARY, DEPARTMENT OF HEALTH, H AND HUMAN SERVICES, National Institutes of Health, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US). (72) Inventors: WEBBER, Mukta, M.; 13543 Wright Road, Eagle, MI 48822 (US). RHIM, John, S.; 11455 South Glen Road, Potomac, MD 20854 (US). (74) Agent: McLEOD, Ian, C.; 2190 Commons Parkway, Okemos, MI 48864 (US).		(81) Designated States: CA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>With amended claims.</i>
(54) Title: HUMAN PROSTATIC CELL LINES IMMORTALIZED BY ADENOVIRUS 12-SIMIAN VIRUS 40 (AD12/SV40) HYBRID VIRUS		
(57) Abstract Immortalized non-tumorigenic or tumorigenic human prostatic epithelial and fibroblast cell lines and derivatives thereof, containing DNA of a hybrid virus between adenovirus 12, and simian virus 40. The cell lines are useful for research on causes, treatment and prevention of prostate cancer, benign prostatic hyperplasia, male infertility, birth defects, aging and assessment of environmental toxic agents.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HUMAN PROSTATIC CELL LINES IMMORTALIZED BY ADENOVIRUS
12-SIMIAN VIRUS 40 (AD12/SV40) HYBRID VIRUS

BACKGROUND OF THE INVENTION

(1) Field of the Invention

The present invention relates to a novel immortalized epithelial cell line containing a hybrid virus and method for its preparation. In particular the present invention relates to a hybrid virus derived from adenovirus 12 and simian virus 40 viruses which is then used for the immortalization of the epithelial cells.

(2) Description of Related Art

Human cells are generally difficult to grow and maintain in long-term cultures *in vitro*. They have a limited life span in culture, grow for a short time and usually after 4 or 5 subcultures, they senescence and die.

Prostate cancer is the leading cancer in men in the United States, in terms of incidence. Thirty-two percent (32%) of all cancers in men arise in the prostate. It is estimated that 200,000 new cases of prostate cancer will occur in the U.S. in 1994. Prostate cancer is the second leading cause of death from cancer and 38,000 deaths are estimated to occur in 1994 (Boring et al., CA, Cancer J. Clin. 44:7, 1994). African American men have the highest incidence of prostate cancer in the world, which is almost twice as high as that in white men and more than 600 times higher than in men from Thailand (Webber et al., In Vitro Models for Cancer Res. Vol. V, pp. 3-24, Boca Raton, CRC Press, 1988). One in 10 men in the U.S. will develop prostate cancer in their lifetime (by age 85). An estimated 11 million men have latent or clinical prostatic carcinoma. Sixty-five percent (65%) of the

-2-

cases already have metastatic disease at the time of diagnosis. The survival rate is less than 20%.

5 The causes of prostate cancer are not known at the present time. A study of the causes, prevention and treatment has been hampered by the fact that good animal or cell models are not available. Although rat prostatic cells have been used extensively for such studies, rat prostate is not homologous to the human prostate, thus, it is not an ideal system to use.

10 There is a need for cell lines derived from normal human prostate which can be used for studies on the process of prostate cancer development in man and to identify agents which may cause or prevent prostate cancer.

15 Attempts have been made to immortalize human adult prostatic epithelial cells using a monkey virus (Simian virus SV40; Cussenot, O., et al., Journal of Urology 143, 881-886 (1991); Kaighn, M. E., et al, Cancer Research, 49, 3050-3056 (1989); Lee et al., Internat. J. Oncol. 4, 821 (1994)).

20 Infection of mammalian cells with Simian virus 40 (SV40) can have two outcomes. In some simian cells which allow multiplication of the virus and are hence called "permissive cells", infection results in virus production and ultimately in cell death. Cells which do not permit virus multiplication are designated as "non-permissive" cells, such as rodent cells. Infection of these cells leads to induction and maintenance of an altered "immortalized" phenotype at a low frequency.

25 Invariably, an integrated copy of viral DNA (vDNA) persists.

30 The viral DNA in non-permissive, SV40-immortalized cells usually cannot be induced to excise itself and replicate, but virus can be induced to replicate after fusion of non-permissive cells with permissive simian cells. According to Gish et al (Gish, W. R., et al., J. Virol., 61:2864-2876 (1987)), two

35

-3-

essential viral components for this excision and lytic replication are cis-acting origin of replication (ori) and a replication component A gene product (large T antigen) acting in trans.

5 In culture, many types of human cells are semi-permissive for SV40 replication. The semi-permissive response of human cells to SV40 infection appears to be complex. Human cells can be productively
10 infected by the virus, but they yield 100 times less virus than the simian cells. A few cells, which survive the lytic infection, may pass through a crisis period to yield immortalized cell lines which carry integrated copies of vDNA (Gish, W. R., et al., J. Virol., 61:2864-2876 (1987)). During this period, the rate of cell
15 multiplication is markedly reduced or ceases. It has also been observed that cultures of SV40-infected human cells that were nursed through crisis no longer produced infectious SV40, although they had done so prior to crisis (Girardi, A. J., et al., J. Cell. Comp. Physiol.
20 65:69-84 (1965)). Furthermore, survivors of crisis exhibited higher levels of T-antigen staining than they did prior to crisis. High levels of T-antigen may be necessary for survival of cells through crisis (Girardi, A. J., et al., J. Cell. Comp. Physiol. 65:69-84 (1965)).

25 Three human cell lines immortalized only by SV40 virus alone have been developed in recent years. Immortalization of human neonatal prostate epithelial cells by strontium phosphate transection method using a plasmid (pRSV-T) containing SV40 was first accomplished
30 by Kaighn et al., (Kaighn, M. E., et al., Cancer Res., 49:3050-3056 (1989)). The plasmid pRSV-T was developed at the National Cancer Institute. It is an SV40 ori construct containing the SV40 early region genes and the Rouse sarcoma virus long terminal repeat (Gorman, C., et al., Science, 221:551-553 (1983)). These cells formed
35 rapidly growing, multi-layered colonies within two weeks and according to the authors, there was little or no

-4-

indication of crisis. These cells contain cytokeratins and SV40-T antigen. They do not produce tumors in nude mice.

5 Cussenot et al (Cussenot, O., et al., J. Urol., 143:881-886 (1991)) used a plasmid containing SV40 genome with defective replication origin (ori-) encapsulated into liposomes. The cells were shown to contain the SV40 genome. They express large T-antigen and are positive for cytokeratins (CK) 18 and 19, weekly
10 positive for prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) and negative for CK 14. These cells contain high affinity receptors for 5 α -dihydrotestosterone (5 α -DHT).

15 In work similar to that of Cussenot et al., (J. Urol. 143:881-886, 1991), Lee et al., (Internat. J. Oncol. 4:821, 1994) used a plasmid (pRNS-1) containing an origin-defective SV40 genome and a plasmid carrying the neomycin resistance gene. A cell line was established, however, this cell line has not been
20 characterized with regard to its prostatic epithelial origin on the basis of androgen responsiveness. These investigators were unsuccessful in establishing an immortalized prostatic epithelial cell line using Ad12-SV40 hybrid virus.

25 Adenoviruses have the ability to extend the lifespan of mammalian cells. When rat embryo cells are infected with adenovirus-2 (AD-2) virus, a fraction of the cells show extended lifespan but infectious virus could not be isolated from them although viral DNA
30 persisted, as recognized by hybridization with labelled probes (Gallimore, P. H., et al., J. Mol. Biol. 89:49-72 (1974)).

35 In 1964, Rabson et al., (Proc. Soc. Exper. Biol. Med. 116:187-190, 1964), reported that the growth of adenoviruses in African green monkey kidney (AGMK) cell cultures is enhanced following pre-infection with SV40 virus. Schell et al (Schell, K., et al., Proc.

-5-

Natl. Acad. Sci. USA, 55:81-88 (1966)) observed that the oncogenicity was markedly enhanced when adenovirus-12 (AD-12) and SV40 were passed serially together for five or more passages in AGMK cells. During the course of their investigation, Schell et al., (Schell, K., et al., Proc. Natl. Acad. Sci. USA, 55:81-88 (1966)) found that hybridization of the two viruses occurred. This hybrid virus was used in the present invention. This is the first successful immortalization of human prostatic epithelial cells with Ad12-SV40 hybrid virus.

OBJECTS

It is therefore an object of the present invention to provide an immortalized normal human prostatic epithelial cell line. Further, it is an object of the present invention to provide an epithelial cell line which is useful for research *in vitro*. A further objective of the present invention is a method for conversion of a non-tumorigenic, immortalized cell into a tumorigenic cell by the introduction of an oncogene. Further, the present invention relates to methods and kits for screening carcinogenic agents or potential chemotherapeutic, chemopreventive, anti-invasive and anti-metastatic agents using an immortalized adult human prostate epithelial cell line. These and other objects will become increasingly apparent by reference to the following description and the drawings.

DESCRIPTION OF THE DRAWINGS

Figure 1A is a photograph of a secondary culture of prostatic epithelium three months after infection with Ad12-SV40 virus. It shows two clones. PWR-1E cell line is a subclone of one of these.

Figure 1B is an uninfected control culture in which all cells have senesced.

Figure 2 is a photograph showing subcloning of a clone of epithelial cells described in Figure 1A. This was done to ensure selection of a true clone. A

-6-

sample plate (shown here) was fixed and stained with crystal violet 15 days after plating and cloning efficiency was also determined.

5 Figure 3 is a microscopic photograph of PWR-1E cells in passage 30, stained with hematoxylin and eosin. These cells have an epithelial morphology (625X).

10 Figure 4 is a graph showing growth of PWR-1E cells. Cells were plated at densities varying from 625 cells/well to 40,000 cells/well, in 96 well plates. Plates were fixed and stained with Methylene blue and absorbance measured at 620 nm earlier (Cai et al., Exper. Cell Res. 192:366, 1991).

15 Figure 5 is a graph showing the growth of PWR-1E in the presence of 5 α -dihydrotestosterone (5 α -DHT). Ten thousand (10,000) cells were plated per well of a 96-well microplate and exposed to varying concentration of 5 α -DHT (10^{-12} M to 10^{-5} M). 5 α -DHT was dissolved in ethanol. PWR-1E cells show a growth response to 5 α -DHT in culture.

20 Figures 6A to 6D consist of microscopic photographs showing immunolabelling of cellular proteins in PWR-1E cells. Proteins were detected by immuno-avidin-biotin- peroxidase staining.

25 Figure 6A is a microscopic photograph showing strong positive staining for cytokeratin 8.

30 Figure 6B is a microscopic photograph showing strong positive staining for cytokeratin 18. This staining demonstrates that PWR-1E cells are of epithelial origin showing expression of cytokeratins characteristic of luminal prostatic epithelial cells.

35 Figure 6C is a microscopic photograph showing absence of staining with antibody to desmin. Desmin is a cytoskeletal protein expressed in muscle cells. This absence of staining further demonstrates that PWR-1E cells are epithelial and not muscle cells.

Figure 6D is a microscopic photograph showing absence of staining with antibody to Factor VIII.

-7-

Factor VIII is expressed by endothelial cells. This absence of staining further demonstrates that PWR-1E cells are epithelial and not endothelial cells (625X).

5 Southern blot analysis shows that PWR-1E cells carry the SV40 large T-antigen gene.

PWR-1E cells are not able to form colonies in soft agar. This demonstrates that, like normal cells, PWR-1E are anchorage dependent.

10 Ten (10) million PWR-1E cells were injected subcutaneously into nude mice. After 4 months none of the animals (0/3) developed tumors. This demonstrates that PWR-1E cells are not tumorigenic.

DESCRIPTION OF PREFERRED EMBODIMENTS

15 The present invention relates to an immortalized human prostatic epithelial or fibroblast cell line in culture, free of other cell lines, containing DNA of adenovirus and simian virus as a hybrid virus. This further includes immortalization and transformation with adenovirus E1A and E1B and simian
20 virus 40 middle-T and large-T antigen genes. The cells can be made tumorigenic by introducing an activated, viral Ki-ras oncogene in the cells.

In particular, the present invention relates to a method for producing immortalized human prostatic
25 epithelial or fibroblast cell lines which comprises: providing human prostatic epithelial or fibroblast cells; and infecting the cells with a hybrid virus derived from an adenovirus and a simian virus to thereby immortalize the cells.

30 Further, the present invention relates to a kit for screening carcinogenic, chemotherapeutic or chemopreventive agents comprising an immortalized human prostate epithelial cell line or derivative thereof containing DNA of adenovirus and simian virus as a
35 hybrid virus.

Finally, the present invention relates to a method for testing carcinogenicity of an agent

-8-

comprising culturing the hybrid virus-containing cell line with an agent suspected of being carcinogenic and determining formation of an abnormal cellular mass by said cell line, the formation of the abnormal cellular mass being indicative of carcinogenicity of said agent.

The epithelial cells containing the hybrid virus (PWR-1E) are deposited under the Budapest Treaty with the American Type Culture Collection in Rockville, Maryland as ATCC CRL 11611. The adenovirus 12 is a publicly available deposit ATCC VR-863, is also described in Schell et al., Proc. Nat. Acad. Sci. 55:81-88, 1966, and is available from many research sources. The simian virus 40 is a publicly available deposit ATCC VR-239, is also described in Schell et al., Proc Nat. Acad. Sci. 55:81-88, 1966 and is available from many research sources.

The PWR-1E cells are of prostatic epithelial origin and express cytokeratins 8 and 18, which demonstrates their origin from the differentiated secretory cells. They do not express desmin, which further demonstrates their epithelial origin and excludes origin from muscle cells. They do not express Factor VIII, which excludes origin from endothelial cells. They were negative for virus production in a "cytopathic effect assay" in Vero cells (Rhim et al., Science 227:1250-1252, 1985). They show a moderate growth response to 5 α -DHT and early passages, without androgen stimulation, were weakly positive for prostate specific antigen (PSA). Preliminary results show that these cells have a normal profile for the expression of plasminogen activators (urokinase and tissue-type plasminogen activator) and type IV collagenases.

-9-

Example 1

1. Isolation and culture of prostatic cells.

Methods for isolation and maintenance of pure cultures of human prostatic epithelium were developed by Webber, (Webber, M. M., In vitro models for prostatic cancer: Summary. In: Models for prostate cancer, G. P. Murphy (ed.) pp. 133-147, New York, NY: Alan R. Liss. (1980); Webber, M. M., Normal and benign human prostatic epithelium in culture. In Vitro, 15: 967-982 (1979); Webber, M. M., In Vitro Models for Cancer Research, Vol. V, pp. 25-125, Boca Raton, FL: CRC Press (1988); Chapronier-Rickenberg, D.M. et al., Growth of Cells in Hormonally Defined Media, 9B:1109-1115, (1982)).

a. Isolation: Isolation and growth of human prostatic epithelium was accomplished according to methods described previously. The medium is serum-free and chemically defined. These studies have been described in detail elsewhere (Webber, M. M., In vitro models for prostatic cancer: Summary. In: Models for prostate cancer, G. P. Murphy (ed.) pp. 133-147, New York, NY: Alan R. Liss. (1980); Webber, M. M., Normal and benign human prostatic epithelium in culture. In Vitro, 15:967-982 (1979); Webber, M. M., In Vitro Models for Cancer Research (Vol. V), pp. 25-125, Boca Raton, FL: CRC Press (1988); and Chaproniere-Rickenberg, D. M., et al., A chemically defined medium for the growth of adult human prostatic epithelium. Cold Spring Harbor Symp. on "Growth of Cells in Hormonally Defined Media.", 9B:1109-1115, (1982)).

The normal primary cultures and earlier passages of PWR-1E cells were grown in the serum-free KGM medium from Clonetics, San Diego, California, supplemented with antibiotic/antimycotic mixture from GIBCO 600-5240 PG, Grand Island, NY (Penicillin 100U, Streptomycin 100 µg and Fungizone 25 µg,). Recent passages have been maintained in K-SFM, a serum-free, defined medium and antibiotic/antimycotic mixture from GIBCO K-SFM, No.

-10-

10005-018, Grand Island, NY. Cells have been frozen successfully and recovered with good viability. A tissue specimen of normal prostate from a 67 year old white male patient undergoing surgery for bladder cancer was used for epithelial cell isolation. Pathology report stated "normal prostate, mild nodular hyperplasia, no neoplasms". The tissue was cut into 2-3 mm cubes and placed in one 100 mm Petri dish with 30 ml RPMI-1640 containing 5% FBS (Intergen, No. 1050-75, Purchase, NY), and 400 Units/ml of collagenase (GIBCO Cat. No. 840-701811, Grand Island, NY) activity 196U/mg, antibiotics/ml as follows: Penicillin 100U, Streptomycin 100 µg and Fungizone 25 µg, Gentamycin 10µg). After 48 hr. digestion in collagenase, the tissue was triturated until all lumps were broken up, and centrifuged to remove collagenase. The pellet was suspended in Saline G and allowed to settle in the refrigerator for 1 hour. The sediment was suspended again and allowed to settle at 4°C. Four such washes were done. The sediment, after the last wash, containing the acini was suspended in storage medium containing spermine (2µg/ml) and left at 4°C overnight to destroy any fibroblasts that may be present in the preparation (Webber, M. M., Cell Biol. Internat. Rep., 4:185-194 (1980)).

b. Culture: The following day, the acini were centrifuged, suspended in growth medium and plated. Primary cultures of prostatic epithelium were established. Growth medium consisted of KGM (keratinocyte growth medium) from Clonetics No. CC-3001, San Diego, California. KGM has 0.2 mM calcium, 0.1 ng/ml EGF and pituitary extract. This medium was supplemented with 10 ng EGF/ml to make sure that the cells were not lost. Previous work has shown that prostate epithelial cells grow well with this EGF supplementation. To further ensure the survival of these cells, culture flasks/plates for growing these cells were coated with a mixture of 10µg/ml each of

-11-

fibronectin and collagen IV (Collaborative Research, No. 40008 and No. 40233, respectively). During the past year, we have been using K-SFM medium from GIBCO, Grand Island, NY for maintaining the cell lines. This medium
5 contains 0.09 mM calcium, 50 µg/ml pituitary extract and 5 ng/ml EGF with no other supplementation.

Primary cultures were subcultured using GIBCO Trypsin: EDTA mixture (0.05% trypsin, 0.02 mM EDTA, No. 25300-013) diluted 1:1 with PBS after one wash with
10 ca/Mg-free Dulbecco's PBS. Cells were plated in coated plates. Medium was changed every third day. These cells were further subcultured to determine the number of passages until senescence and cell loss. These cells could not be propagated beyond five passages.

15 **2. Immortalization by infection with AD12-SV40 hybrid virus:** Primary and secondary cultures were used for this infection. AD12-SV40 preparation (1:10 dilution) was used (Rhim, J. S., et al., Proc. Natl. Acad. Sci. USA, 78:313-317 (1981)). Several cultures were infected.
20 Untreated control cultures were also maintained and medium was changed twice weekly. After 10 days the infected cultures were subcultured and plated in coated plates. Cells were fed every third day. One month after infection, colonies began to appear and some areas
25 of the culture showed cytopathic effects, whereas, the control cultures showed signs of degeneration. Two weeks later, clones from infected cultures were isolated. These were plated into coated 24-well plates. Twenty-four (24) clones were isolated. One clone grew
30 rapidly and was further propagated through several passages. This clone did not show any cytopathic effects and cells had an epithelial morphology. Cells from passage 10 were recloned by plating 1000 cells per 100 mm plate. Cloning efficiency of this population was
35 4.4%. These clones were further subcloned by dilution plating of single cells in 96-well plates. Sixty-six (66) clones were isolated and further propagated.

-12-

Figure 2 shows the second cloning of cells. From this cloning, an AD12-SV40 immortalized, non-malignant cell line, designated as PWR-1E cells has been established. At present, passage 35 cultures of PWR-1E cells show epithelial morphology, and they are of a uniform size and shape. The cell sheets look excellent in terms of morphology. The cultures do not show any cytopathic effects. These cells have undergone over 250 cell generations.

The AD12-SV40 virus consists of recombinant DNA containing all or part of the SV40 genome and part or all of the adenovirus genome enclosed in adenovirus capsids. The AD12-SV40 hybrid virus was found to be highly oncogenic in newborn hamsters.

An advantage of using AD12-SV40 hybrid virus for immortalization is that cultures infected with the hybrid virus escape the extended "crisis" period, lasting as long as several months, experienced by cultures infected only with SV40 virus. This was demonstrated by Reddel et al., (Reddel, R.R., et al., Cancer Res. 48:1904-1909 (1988)) using human bronchial epithelial cells. However, these cells did not express the adenovirus early region proteins E1A and E1B. Cells immortalized with adenoviruses retain many of the characteristics of parent normal cells (Emami, S., et al., Proc. Natl. Acad. Sci. USA, 86:3194-3198 (1989)).

Immortalization with Ad12-SV40 hybrid virus is especially important when one analyzes the process of immortalization and malignant transformation by oncogenic DNA viruses. Adenovirus and SV40 viruses encode certain proteins which are associated with the ability to immortalize and induce malignant transformation.

Once the cells were immortalized, an extensive characterization of immortalized cells was essential before they could be used as a cell model system as follows.

-13-

Example 2

1. Characterization of cells on the basis of intermediate filament and other proteins: PWR-1E cells were characterized first to establish their epithelial origin on the basis of keratin expression. Expression of cytokeratins 8/18 pair associated with prostatic epithelial cells was examined. PWR-1E cells showed strong expression of both cytokeratins 8 and 18. The presence of keratins 8 and 18 proves, beyond doubt, the epithelial origin of PWR-1E cells and eliminates the possibility of fibroblastic origin since fibroblasts do not express keratins.

Intermediate filaments (IFs) are an essential component of the developmental program of different cell lineages (Sommers, C. L., et al., Cancer Res., 52:5190-5197 (1992)). By knowing the IF proteins expressed by cell lines, it becomes possible to characterize the origin of the cells. For example, cells of simple epithelia coordinately express certain cytokeratins. Thus, IFs can serve as useful markers for characterization of cells. IFs are constituents of virtually all differentiated cells and are one of the components of the cell cytoskeleton expressed in a tissue specific manner (Sommers, C. L., et al., Cancer Res., 52:5190-5197 (1992)). Cells of epithelial origin normally express cytokeratins while those of mesenchymal origin express vimentin IFs (Sommers, C. L., et al., Cancer Res., 52:5190-5197 (1992)). In addition to cytokeratin expression in PWR-1E cells, expression of other IF proteins was also examined to make certain that our cell line did not originate from any cell type other than prostate epithelium.

a. Cytokeratins: An important index of differentiation is the pattern of cytokeratin expression. Keratins are expressed in a cell and tissue-specific manner and their expression is known to change in abnormal differentiation processes. A human

-14-

keratinocyte cell line KER-1 immortalized with large-T antigen gene shows a cytokeratin profile similar to that of non-immortalized keratinocytes except that KER-1 cells express higher levels of cytokeratins 13 and 19 (Agarwal, C, et al., Cancer Res., 50:5947-5953 (1990)).

Normal epithelial cell differentiation is marked by the production of distinct cytokeratin IFs. They consist of a family of about 20 polypeptides in the Mr range of 40 kDa to 70 kDa that are translated from distinct mRNAs derived from a large multigene family. All epithelial cells co-express at least one pair of cytokeratins, consisting of an acidic and a basic protein and these associate to form the IFs (Molloy, C. J., et al., Exp. Mol. Pathol., 49:128-140 (1988)). As epithelial cells differentiate, additional keratins are expressed or some may cease to be expressed. Thus, the appearance of specific cytokeratins is also a useful marker for identifying the level of differentiation (O'Guin, W.M., Schermer, A., Lynch, M. and Sun, T.: Differentiation-specific expression of keratin pairs. In: Cellular and Molecular Biology of Intermediate Filaments, R.D. Goldman and P.M. Steinert eds.), New York, Plenum Press, pp. 301-334, 1990. Cytokeratin expression can serve as a unique marker for prostatic epithelial cell differentiation (Sherwood, E. R., et al., Prostate, 18: 303-314 (1991)). The prostatic epithelium is a simple epithelium, consisting of less differentiated basal cells and more differentiated luminal cells with a specialized secretory function (Sherwood, E. R., et al., Prostate, 18: 303-314 (1991)). CK 8 and 18 have been identified as luminal cell specific markers and CK 5 and 15 as basal cell specific marker pair. CK 8, a 52 kDa basic protein, pairs with the acidic CK 18 (Mr 45 kDa). Overwhelming data show that the selective co-expression of CKs is highly conserved in various epithelial lineages.

b. Desmin: To prove that the PWR-1E cells are

-15-

not of smooth muscle origin, expression of desmin was examined. Epithelial cells should not express desmin. Desmin (Mr 53 kDa) IFs are found in smooth muscle cells (SMC), and in skeletal and cardiac muscle. A broad
5 range of soft tissue tumors, e.g., sarcomas express desmin but carcinomas and melanomas do not. Desmin has not been found in normal epithelia or epithelial tumors (Truong, L. D., et al., Am. J. Clin. Pathol., 93: 305-314 (1990)). PWR-1E cells were negative for desmin.
10 This demonstrates that PWR-1E cells are epithelial in origin.

2. Characterization on the basis of differentiated functions of prostatic epithelial cells:

15 a. Hormonal response: *In vivo* the growth and functional response of prostatic epithelium to androgens is reflected by limited stimulation in cell proliferation and the expression of PSA, PAP (Lin, M.-F., et al., Cancer Res., 52:4600-4607 (1992); and Fong, C.-J., et al., Prostate, 21:121-131 (1992)). Secretion
20 of both PSA and PAP responds to androgen stimulation. The presence of androgen receptor would be another marker for establishing prostatic epithelial origin. Therefore, effect of 5 α -DHT on the growth of PWR-1E
25 cells, the expression of PSA and PAP and the presence of androgen receptor are being examined. It should however be emphasized that many transformed cell lines derived from hormone responsive normal cells lose hormone
30 receptor and their ability to respond to that specific hormone. Examples include DU-145 and PC-3 human prostate carcinoma cell lines (Webber, M. M., In vitro models for prostatic cancer: Summary. In: Models for prostate cancer, G. P. Murphy (ed.) pp. 133-147, New York, NY: Alan R. Liss. (1980)).

35 Very few studies have been done on the effects of 5 α -DHT on the growth of normal human prostatic epithelium. Prostatic epithelial cells will grow in

-16-

culture in the absence of androgen, however, they are androgen responsive. In one of her earlier studies, Webber has shown (Webber, M. M., *In vitro* models for prostatic cancer: Summary. In: *Models for prostate cancer*, G. P. Murphy (ed.) pp. 133-147, New York, NY: Alan R. Liss. (1980)) that the growth of normal human prostatic epithelium was stimulated three to four fold in the presence of 0.3 μ M 5 α -DHT (Webber, M. M., *Growth and maintenance of normal prostatic epithelium in vitro* -A human cell model. In: G. P. Murphy, A. A. Sandberg and J. P. Karr (eds.), *Models for Prostate Cancer*, pp. 181-216, New York: Alan R. Liss. (1980)). The majority of studies on the effects of androgens on prostatic cells in culture have been done using the prostatic carcinoma cell line LNCaP. Generally in culture, 5 α -DHT doses considerably higher than those that induce cell proliferation cause increased secretion of PSA and PAP proteins. For example, the earliest studies by Horoszewicz et al on LNCaP cells showed a 1.9 fold stimulation of cell growth with 1 nM to 0.1 μ M 5 α -DHT in cultures containing charcoal stripped serum. These cells also contained 210 fmol androgen receptor/mg cytosol protein (Horoszewicz, J.S., et al., *Cancer Res.*, 43: 1809-1818 (1983)). They observed increase in PAP secretion at the entire range of 5 α -DHT tested. However, much variation exists amongst results reported in different studies. Hasenson et al (Hasenson, M., et al., *Prostate*, 7:183-194 (1985)) observed only a weak cell proliferation response in LNCaP cells to 10 to 100 nM 5 α -DHT and found only 16 fmol androgen receptor/mg protein. de Launoit et al., (de Launoit, Y., et al., *Cancer Res.*, 51:5165-5170 (1991)) observed a biphasic effect on LNCaP cell proliferation with a maximum stimulation at 0.1 nM 5 α -DHT and reduced cell proliferation to normal levels at higher concentrations. Simard et al. (Simard, J., et al., *Cancer Res.*, 51:4336-4341 (1991)) observed stimulation

-17-

of cell proliferation at 0.5-1 nM 5 α -DHT after a 10 day exposure and an increase in apolipoprotein D secretion at 5 nM to 1 μ M. Other investigators have studied the effects of the non-metabolizable, synthetic androgen R1881. Growth stimulation was observed from 0.1 nM to 0.1 μ M (Berns, E.M.J.J., et al., Prostate, 9:247-259 (1986); and Langelier, E. G., et al., Prostate, 23:213-223 (1993)). At 1 nM and higher concentrations, stimulation of PAP secretion was observed (Langelier, E. G., et al., Prostate, 23:213-223 (1993)). These differences in hormonal response in different studies may be due to different culture conditions, different sublines or vastly different passages of LNCaP that may have been used in different studies. Other reasons may be the rapid metabolism of 5 α -DHT in cell cultures. Berns et al observed that ~50% of the added (25 nM) 5 α -DHT is metabolized within 2 hours in prostate cell cultures. They also showed that the proliferative response of cells also depended on the cell number plated (Berns, E.M.J.J., et al., Prostate, 9:247-259 (1986)).

b. Assay for responsiveness to androgens: A microplate assay for establishing effects of androgens on the growth of cell lines was used. This assay has been routinely used by Webber and other study growth modulation (Cai, D., et al., Exp. Cell Res., 192:366-372 (1991)). 5,000 or 10,000 cells were plated/well of a 96-well plate in 200 μ l of serum-free K-SFM. After 24 hours, medium was changed to media containing a range of concentrations of 5 α -DHT. Medium containing 5 α -DHT was changed every 48 hrs. Test plates were taken after 7 and 9 days of treatment and stained with the protein-binding dye, methylene blue. Bound dye was released with 1% sodium dodecyl sulfate (SDS) and absorbance measured at 620 nm with a microplate reader according to a method described earlier (Cai, D., et al., Exp. Cell Res., 192:366-372 (1991)). The results are shown in

-18-

Figure 5.

The prostatic epithelial origin of PWR-1E cells was confirmed by examining PSA and PAP expression, responsiveness to androgens and the presence of androgen receptor. It should, however, be noted that the immortalized neonatal prostatic cell line developed by Kaighn et al (Kaighn, M. E., et al., Cancer Res., 49:3050-3056 (1989)), does not express PSA or PAP and their prostatic carcinoma cell line also does not express PSA, expresses very low levels of PAP and is unresponsive to androgens (Kaighn, M. E., et al., Cancer Res., 49:3050-3056 (1989)). PWR-1E cells showed a moderate growth response to 5 α -DHT treatment. Additional experiments are in progress using other, more stable androgens.

c. Differentiation: Differentiated, secretory prostatic epithelial cells secrete PSA and isozyme II PAP (Lin, M.-F., et al., Cancer Res., 52:4600-4607 (1992)). These proteins can be used as specific markers for establishing that the immortalized cells are: 1) of prostatic epithelial original, and 2) that they are capable of secreting these proteins, as they do *in vivo*. Both PSA and PAP are androgen responsive and their secretion can be modulated in androgen-responsive cells *in vivo* and *in vitro*, e.g., by exposure to 5 α -DHT. The expression of these two proteins in response to "Mibolerone" a non-metabolizable androgen, and of androgen receptor in PWR-1E cells is being examined to demonstrate beyond doubt their prostatic epithelial origin. The primary and secondary cultures from which PWR-1E cells were derived, were positive for PSA.

It is important to note that a moderate growth response and PSA and PAP expression in response to 5 α -DHT of cultures grown in serum-free medium may be due to the presence of epidermal growth factor (EGF) in the medium which is invariably a component of serum-free media. EGF is a potent inducer of cell proliferation in

-19-

epithelial cells. It has been shown that addition of EGF to medium containing 5% fetal calf serum contributes to the loss of steroid binding (Schuurmans, A. L., et al., Int. J. Cancer, 42:917-922 (1988)). Experiments on 5 α -DHT growth response and PSA and PAP expression were conducted in K-SFM medium (GIBCO, Grand Island, NY) which contains 5 ng/ml EGF. These experiments need to be done using less or no EGF, if possible. This effect of EGF can be explained by the observation that cell proliferation and expression of differentiated function in response to androgens, such as 5 α -DHT, have an inverse relationship.

PWR-1E cells express SV-40 large-T antigen. They were non-tumorigenic when tested for tumorigenicity in nude mice. They grow in a serum-free defined medium with a doubling time of about 40 hours.

d. Plasminogen activator (PA) expression: Differentiated prostatic epithelial cells normally secrete both tissue-type (t-PA) and urokinase-type (u-PA) PAs which form an important component of the seminal fluid (Webber, M. M., et al., Retinoic acid modulates urokinase-type plasminogen activator expression in DU-145 human prostate carcinoma cells (In preparation) (1994)). These enzymes can serve as an additional marker for prostatic epithelial function, especially as urokinase expression responds to testosterone exposure and could be used for early detection of prostate cancer. Expression of plasminogen activators and type IV collagenases in PWR-1E cells is similar to that in normal prostatic epithelium.

e. Assays for plasminogen activator activity;
i. Zymography: Conditioned media from cultures of normal prostatic epithelium, PWR-1E cells and DU-145 human prostate carcinoma cells were subjected to SDS-PAGE zymography. Results show that the level of u-PA activity in PWR-1E cells is similar to that in normal cells, whereas, the malignant cells express

-20-

considerably higher levels of u-PA.

5 ii. **Chromogenic substrate assay:** The activity of urokinase (u-PA) in conditioned media was also determined by a chromogenic substrate assay where the increase in absorbance of the free chromophore generated was measured and compared to the original u-PA specific substrate per unit time at 405 nm. At excess substrate concentration, the rate of absorbance increases due to the amount of chromophore released and is linearly related to enzyme concentration (Webber, M. M., et al., A. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostate carcinoma cells, In preparation, (1994)).

10 f. **Type IV collagenase expression:** Secretion of type IV collagenase was examined using SDS-PAGE zymography using gelatin or type IV collagen as substrates and samples of conditioned medium from PWR-1E cells cultures were tested. Preliminary results show that collagenase expression in PWR-1E cells is similar to that in normal prostate epithelial cells. These results provide one more normal characteristic maintained by PWR-1E cells.

Example 3

25 1. **Isozyme analysis:** Human origin of PWR-1E cells was established by isozyme analysis. PWR-1E cells have the following isozyme profile: LDH, human (lactate dehydrogenase); NP, human (purine nucleoside phosphorylase); G6PD, B (glucose-6-phosphate dehydrogenase); PGM1, 1 (phosphoglucomutase-1); PGM3, 1 (phosphoglucomutase-3); ESD, 1 (esterase D); Me-2, 0 (malic enzyme, mitochondrial); AK-1, 1 (adenylate kinase); GLO-1, 2 (glyoxalase-1).

35 2. **Karyotype analysis:** A complete chromosome analysis was performed to establish that the cells are of human male origin. Chromosome number, presence of the Y

-21-

chromosome, stable translocations, marker chromosomes and G-banding pattern were examined.

5 The cell line is aneuploid human male, with most chromosome counts in the hypotriploid range. A normal Y chromosome is present in about 20% of metaphases. Normal chromosomes #1, #2, #9, #14, #16, #17, #18, and #22 are most often trisomic; chromosomes #5, #15, #20, and #21 are usually tetrasomic; while the remainder of normal chromosomes are usually disomic.

10 Cytogenetic alterations, other than copy number, are not prominent: most chromosomes are normal. Cells other than those of cell line PWR-1E p17 were not detected in the culture. They are hypotriploid and carry a Y chromosome. Twenty percent (20%) of the cells contain

15 a normal Y chromosome.

3. Cytopathic effects assay in Vero cells: The PWR-1E cells were tested for free virus production, using this assay in the sensitive Vero cells (Rhim, J. S., et al., Science, 227:1250-1252 (1985)). This assay was

20 performed to establish that PWR-1E cells were a non-producer cell type. Only those immortalized cells that have an integrated viral genome and are not shedding the virus are useful. The Vero cell line is derived from

25 the kidney of a normal, adult African green monkey. Vero cells (ATCC CCL 81) are permissive for the growth of SV40 and adenoviruses which results in a lytic infection of cells, producing cytopathic effects (CPE).

Vero cells were grown in Dulbecco's MEM with

30 5% fetal bovine serum. Ten thousand (10,000) Vero cells were plated per well in 6-well plates. At 50% confluency, cultures were inoculated, in duplicate, with 500 μ l of undiluted and diluted (1:2, 1:4, 1:8, 1:10), four-day conditioned medium from PWR-1E cells. Cells

35 were maintained for 21 days and observed periodically for cytopathic effects. Conditioned medium from PWR-1E cells did not cause CPE in Vero cells, hence, they are

-22-

a non-producer cell line.

4. **Growth curves:** Cells were plated in 96-well plates at different densities varying from 625 cells to 40,000 cells per well in triplicate. Medium was changed every 48 hours. Plates were taken at 48 hr. intervals, beginning with 2 days after plating, fixed, stained and prepared for reading absorbance as described earlier (Cai, D., et al., Exp. Cell Res., 192:366-372 (1991)). Growth curves for PWR-1E cells are shown in Figure 4. These cells have a doubling time of about 40 hrs.

5. **Immunoperoxidase and immunofluorescence methods:** Expression of cytokeratins, desmin, Factor VIII, PSA and PAP protein expression was detected using monoclonal antibodies (MoAbs) and avidin-biotin immunoperoxidase (Vector ABC kit No. PK-6102) or immunofluorescence methods (Antibodies: A Laboratory Manual., New York: Cold Spring Harbor laboratory, pp. 359-413, (1988)). MoAbs are available for all of the antigens to be tested, from Sigma, St. Louis, Missouri (CK 8, No. C-5301; CK 18, No. C-8541,) and Dako, Carpinteria, California (Desmin, No. D-1033; Factor VIII, No. F-3520, PSA, No. M-750). Two different sets of cultures were tested for each cell line. Appropriate controls employing non-immune serum were used. The results are shown in Figures 6A to 6D.

6. **Agar assay for anchorage independence:** Normal cells do not form colonies in soft agar. Immortalized PWR-1E cells did not form colonies in agar. Thus, like normal cells, they are anchorage dependent, while the malignant cells will be expected to form colonies. DU-145, human prostate carcinoma cells, form colonies in agar, and are used as a positive control. Colonies of anchorage independent cells appear in 3-5 weeks.

-23-

7. **Growth in nude mice:** Ten (10) million cells were injected subcutaneously in 3 mice. Mice were examined periodically for tumor development and were maintained for four months. After four (4) months, none of the 3 mice injected with PWR-1E cells had developed tumors at the site of injection. Hence, PWR-1E cells are not tumorigenic.

8. **Lack of invasive ability:** It was anticipated that the immortalized cells would not be invasive in an *in vitro* invasion assay using our constituted basement membrane. Results show that PWR-1E cells are non-invasive as compared to carcinoma cell lines.

a. **In vitro assay for invasive potential of cells:** This assay involves the use of Boyden chambers where cells plated on top of a porous filter coated with a reconstituted basement membrane "matrigel," in the upper chamber were allowed to invade and migrate through matrigel for a period of 6 hrs. The lower chamber contained fibroblast conditioned medium as a chemo-attractant. The speed of migration correlates with the invasive potential (Webber, M. M., et al., A. Retinoic acid modulates extracellular matrix degradation mediated by proteases secreted by prostatic carcinoma cells, in preparation, 1994; Kleinman, H. K., et al., Biochemistry 25:312-318 (1986); Albini, A., et al., Cancer Res., 47:3239-3245 (1987)). Cells migrate to the underside of the filter, which are then stained on the filter with HEMA 3 (Curtin Matheson, Houston, TX, USA). The nuclear stain is then extracted with 0.1N HCl and absorbance is measured using a Microplate reader (Grotendorst, G. R., Methods Enzymol., 147: 144-152 (1987)). The number of cells migrated shows a correlation with absorbance.

9. **Expression of viral antigens:** The expression of SV40 large-T antigen in PWR-1E cells was examined. SV40

-24-

immortalized cells have been shown to carry the immortalizing, large-T antigen gene (Gish, W. R., et al., J. Virol., 61:2864-2876 (1987); and Reddel, R. R., et al., Cancer Res., 48:1904-1909 (1988)). PWR-1E cells
5 express the large-T antigen.

10. Prostate pathology: An analysis of the pathology of the prostate shows that the incidence of latent carcinoma of the prostate is about the same worldwide
10 (Webber, M. M., et al., In Vitro Models for Cancer Research, Vol. V., pp. 3-24, Boca Raton, FL: CRC Press. (1988)). However, the high incidence American male population shows a higher percentage of more aggressive, invasive-type latent carcinomas which develop into
15 clinical carcinomas, compared to low incidence populations which show less aggressive, non-invasive-type, latent carcinomas. New evidence indicates that the precancerous lesions appear at a young age in men in their twenties and thirties (Bostwick, D. G., J. Cell.
20 Biochem., 164:10-19 (1992)). This suggests that there is a long latent period of 20 to 30 years before cancer develops. Early changes during this period are an excellent target for cancer prevention. The best cure for cancer is prevention. The availability of
25 immortalized cell lines makes it possible to test agents which could be used for cancer prevention, starting at a young age when cancers appear to first originate.

Example 4

30 1. Immortalization and the phenomenon of senescence: Senescence appears to be characteristic of all normal human cells in vivo and in culture. SV40 transformed human cells typically have extended in vitro lifespan but eventually reach a stage referred to as "crisis",
35 where the cultures become static and cell proliferation is greatly reduced or ceases. The parent cultures of PWR-1E cells did not experience this crisis phase

-25-

because cells infected with the hybrid virus escape the crisis stage.

Clone formation and immortalization were achieved at a high efficiency because the primary cells used for virus infection were grown in a serum-free medium. Many epithelial cells, especially epidermal-like cells are usually induced to terminally differentiate in serum-supplemented medium because TGF- β is a major serum-derived inhibitor (Stoner, G. D., et al., Cancer Res., 51:353-371 (1991)). As a result of this differentiation, many virus-infected cells would terminally differentiate and would be lost. Establishment of well characterized, human, non-malignant cell lines allows detailed investigation of many aspects of the normal prostatic epithelial cell physiology and of prostate tumors. Such immortalized and well characterized human prostate cell lines are not presently available. PWR-1E provides a useful tool to study the biology and the pathology of adult prostatic epithelial cells, specifically to understand the steps leading to prostatic transformation.

Malignant transformation of mammalian cells requires at least two separate functions i) the establishment function is concerned with immortalization of cells and ii) transformation function is required for full expression of an oncogenic phenotype (Ruley, H. E., Nature, 304: 602-606 (1983)). For example, Polyoma virus middle-T and the T24 Harvey ras 1 gene are unable individually to transform primary baby rat kidney cells. However, adenovirus early region E1A gene provides functions required by these genes to transform cells. Also, early region E1B is unable to transform cells in the absence of E1A. E1A immortalizes and E1B transforms, therefore, both are needed for malignant transformation. The immortalization step enables cells to respond to growth factors and to the action of transforming proteins (Ruley, H. E., Nature, 304: 602-

-26-

606 (1983)).

2. Some examples which demonstrate the cooperate nature of immortalizing and transforming genes: H u m a n
5 keratinocytes were immortalized by infection with AD12-SV40 hybrid virus. These cells are not tumorigenic. Subsequent infection with Kirsten murine sarcoma virus, i.e., with Ki-ras oncogene resulted in the acquisition of neoplastic properties. These results support the
10 multistep process of carcinogenesis (Rhim, J. S., et al., Science, 227:1250-1252 (1985)). Neither control nor Ki-MSV infected cells could be propagated serially beyond 2 or 3 subcultures. In contrast, AD12-SV40 infection led to the appearance of actively growing
15 colonies by 3 to 4 weeks. By week 6, T-antigen was revealed in the nuclei. Cells contained SV40 transcripts but not AD12. No transcripts were detected from adenovirus E1A and E1B regions in these transformed human cells (Rhim, J. S., et al., Science, 227:1250-1252
20 (1985)). Infection of primary baby rat kidney cells with adenovirus 5 resulted in increase in cell proliferation. These cells produced a growth factor which stimulated the growth of primary cultures (Quinlan, M. P., et al., Proc Natl. Acad. Sci. USA, 84:3283-3287 (1987)). Results suggest that E1A exerts
25 its transformation potential through interactions with products of the tumor suppressor genes (Whyte, P., et al., Cell, 56:67-75 (1989)).

Chimpanzee skin fibroblasts immortalized with
30 AD12-SV40 virus contained AD12 and SV40 antigens and produced virus. However, at passage 9, one line became non-producer and did not show virus-specific antigens. Hybrid virus could not be rescued from these cells by co-cultivation with Vero cells ((Rhim, J. S., et al., Proc. Natl. Acad. Sci. USA 78:313-317 (1981)).
35

In summary, we have established an AD12-SV40 immortalized cell line PWR-1E, derived from human

-27-

prostatic epithelium. PWR-1E cells express many characteristics of normal epithelial cells and are non-tumorigenic cells. Cells show a growth response to 5 α -DHT. Experiments to accomplish further characterization are in progress. These cells provide an important model for studies on prostate carcinogenesis.

The following description demonstrates the significance of the novel non-malignant cell lines: The applications for the cell lines are in the areas of causes, prevention and treatment of prostate cancer and of benign prostatic hyperplasia (BPH); role of diet and nutrition in cancer; aging research; cell physiology; studies on the mechanisms of secretion; cell biology; biochemistry; studies on cell differentiation; developmental biology; and all biomedical sciences.

1. Acquisition of normal human tissue: Specimens of normal human prostate are very difficult to obtain because of the availability and consent concerns. Since PWR-1E cells retain many characteristics of normal cells, they may be used in experiments in place of normal cells, which are generally not available to most investigators.

2. Human cell models: Use of human cell models is considered much more appropriate than using rat or mouse cells, data from which then have to be extrapolated to the human condition.

3. In vitro models: Use of cell models for research is preferred as much as possible in order to avoid unnecessary use of whole animals.

The cell lines can be used for research in the following and other areas:

4. Cancer detection and diagnosis: As models for the discovering new markers for early detection of prostate cancer and BPH.

5. Cancer treatment:

(a). The cells, transformed as described

-28-

above, can be used as cell systems for the discovery of new drugs such as cisplatin and taxol for the treatment of prostate cancer and BPH.

5 (b). As cell models for examining the efficacy of single drugs and combination of drugs and/or radiation for the treatment of prostate cancer.

10 (c). As cell systems for identification of anti-invasive agents, such as protease inhibitors, i.e., inhibitors of urokinase and type IV collagenase, and other agents which can specifically prevent invasion, including anti-motility factors, and thus can be used to prevent cancer from invading the neighboring tissue.

15 (d). As cell models for the identification of anti-metastasis agents, which can specifically prevent cancer from spreading to distant organs.

(e). As cell models for the identification of anti-angiogenic agents, which can specifically prevent growth of new blood vessels into the tumor.

20 **6. Cancer prevention:** As models for the discovery and testing of agents which may have the ability to prevent prostate cancer and benign prostatic hyperplasia.

7. Basic Research: The cell models can be used for a large variety of studies, for example:

25 (a). The immortalized human prostatic cells are especially useful for studying the etiology and multistep process of carcinogenesis in the prostate. This immortalized prostatic cell line, capable of growth in serum-free medium, is useful for studying neoplastic transformation and the multistep process of
30 carcinogenesis involving initiation and promotion in the prostate and for investigating the action of putative prostatic carcinogens. This may include oncogenes, chemical carcinogens and promoters, and radiation. These cells can also be used for the identification of
35 carcinogenic agents and the process of cancer development in the human prostate.

(b). For the identification of agents which

-29-

cause benign prostatic hyperplasia and the process of BPH development.

5 (c). For the identification of specific genetic defects, in the multi-step process of carcinogenesis, which lead to the development of prostate cancer.

(d). For studies on why prostate cancer does not respond well to chemotherapy.

10 (e). For studies on the mechanisms of drug resistance in prostate cancer and how to circumvent resistance.

(f). Cells immortalized with this hybrid virus can be used to study:

15 i. The interactions between the tumor suppressor gene encoded host cell proteins, such as p53 and pRB and the viral immortalizing genes such as adenovirus E1A and SV40 large-T antigen. As shown in Table 1, viral proteins are able to bind and sequester the suppressor proteins, thus, allowing uncontrolled growth. The E1A and SV40 large-T antigens prevent the suppressor proteins from performing their normal function, which is to suppress cell proliferation. Loss or abnormal expression of p53 or pRB is associated with increased risk for cancer.

25 ii. The role played by suppressor genes in prostate cancer.

iii. The multistep process of carcinogenesis in the human prostate.

30 iv. Escape from senescence, i.e., immortalization. This is important not only for improving our understanding of the aging process but also of cancer since malignant transformation results in the development of immortal cells.

-30-

Table 1

	<u>Viral protein</u>	<u>Suppressor gene protein</u>
	SV40 large T antigen	p53, pRB
	E1A of adenovirus	pRB
5	E1B of adenovirus	p53

Normal cells undergo senescence and are lost. However, immortalization with AD12-SV40 allows a study of escape from aging and death. SV40 infected human cells go through a "crisis" phase which may last a year or more, whereas, cells infected with the hybrid virus escape this crisis phase and clones of immortalized cells can be selected rapidly. Since prostate cancer incidence increases with age, this cell model would be especially useful for studies on aging and acquisition of immortality.

(g). Basic understanding of prostate physiology and its role in reproduction.

8. Mechanisms of tumor progression: Tumor progression itself is a multi-step process which includes invasion, metastasis, angiogenesis and the development of drug resistance. The expression of proteases such as urokinase and collagenase, is associated with progression. The cells can be used for studies, for example:

(a). The mechanism of tumor progression and the associated genetic and epigenetic changes.

(b). Increased expression of the above mentioned proteases and their appearance in the blood of cancer patients may serve as an indicator/marker of the advanced stage of the disease. Thus, the cell lines can be used for the identification of agents which decrease or modulate protease activity and thus, may be useful cancer prevention, intervention and therapeutic agents. These agents include anti-invasive and anti-metastatic agents. Levels of these proteases in the blood could also be used as indicators of treatment efficacy.

-31-

(c). Tumor progression is also associated with angiogenesis. These cell lines can be used for the identification of anti-angiogenic agents.

9. Models for risk assessment of reproductive toxicity:

5 Reproductive toxicity may result in infertility in men, spontaneous abortions in their female partners and birth defects in their offspring. This cell line and derivatives thereof, can be used as:

10 (a). A model for identification of reproductive toxins which may be secreted into the seminal fluid and thus, damage sperm, resulting in abortions and birth defects.

(b). A model for detection of exposure to environmental and industrial reproductive toxins.

15 (c). A model for detection of reproductive toxicity in men exposed to chemicals in chemical warfare.

20 (d). A model for infertility and for birth defects in the offspring of men exposed to toxic chemicals in the industry and in chemical warfare.

(e). A model for studies on organ specific toxicity, and especially for studies on the transport of toxins into the seminal fluid by prostatic cells. This cell model would be useful for studying uni-directional transport and secretion of toxins into the seminal fluid and their effect on sperm. For instance, evidence is accumulating to suggest an association of pesticides with birth defects and cancer. Some of these toxins may be passed to infants via human milk. Others may damage sperm by their presence in the prostatic fluid which provides a vehicle for sperm. The availability of well characterized human prostatic epithelial cell lines will provide useful models for studies on infertility and birth defects.

35 10. Cells to be used as "normal" controls, when samples of human prostate are not available: These cells retain many characteristics of normal epithelial cells, e.g.,

-32-

normal cytokeratin expression of cytokeratins 8 and 18, absence of desmin or Factor VIII expression, contact inhibition and monolayer formation in culture, response to 5- α dihydrotestosterone, anchorage dependence and inability to grow in agar, inability to form tumors in nude mice and normal protease profiles. Since PWR-1E cells express many of the characteristics of normal differentiated prostatic epithelial cells, they can be used for certain studies in place of normal human prostatic epithelial cells, which are very difficult to acquire. This is a useful model for those studying the processes of cell secretion, for example, in cystic fibrosis patients.

11. Studies on uni-directional transport of secretory proteins: PWR-1E cells are useful for studying such differentiated functions as uni-directional transport and secretion of prostate specific proteins.

12. Identification of potential chemotherapeutic drugs: These cells are useful for screening chemicals suitable for the treatment of cancer and related diseases, by growing them *in vitro* in medium containing the chemical to be tested and then, after a suitable period of exposure, determining whether and to what extent cytotoxicity has occurred, e.g. by trypan blue exclusion assay or related assays (Patterson, Methods Enzymol. 58:141 (1979)), or by growth assays such as colony forming efficiency (MacDonald et al., Exp. Cell. Res. 50:417 (1968)), all of which are standard techniques well known in the art.

Similarly, potential chemotherapeutic drugs may be screened *in vivo* in suitable animal models. The tumorigenic or nontumorigenic human prostate epithelial cell lines are injected subcutaneously into athymic nude mice. Potential chemotherapeutic drugs are injected at various time intervals and doses. Animals are examined weekly for the presence of tumors for a period of four or more months.

-33-

13. **Studies of metabolism of carcinogens and other xenobiotics:** Carcinogens and other xenobiotics may be added to the growth medium of cultures of these cells and then the appearance of metabolic products of these compounds may be monitored by techniques such as thin layer chromatography or high performance liquid chromatography and the like. The interactions of the compounds and/or their metabolites with DNA can then be examined.
14. **Studies of DNA mutagenesis:** Substances known or suspected to be mutagens may be added to the growth medium of cultures of PWR-1E cells and then mutations may be assayed, e.g., by detection of the appearance of drug resistant mutant cell colonies (Thompson, Methods Enzymol., 48:308 (1979)). Similarly, cell-mediated DNA mutagenesis in PWR-1E cells can be examined by co-cultivating them with a cell type known to have the ability to activate a procarcinogen and, thus, release mutagenic metabolites into the culture medium (Hsu et al., Proc. Natl. Acad. Sci. USA 75:2003 (1978)).
15. **Studies of chromosome damaging agents:** Substances known or suspected to cause chromosomal damage may be added to the culture medium of these cell lines, and then the extent of chromosomal damage may be measured by techniques such as measurement of the frequency of sister chromatid exchange (Latt et al. In: Tice, R. R. and Hollaender, A., Sister Chromatid Exchanges, New York: Plenum Press, pp. 17-40, (1982)).
16. **Studies of malignant transformation:** By chemical, physical and viral agents, and transferred genes including oncogenes and high molecular weight genomic DNA from tumors, using standard assays such as tumor formation in athymic nude mice.
17. **Studies of cellular responses to growth factors and production of growth factors:** Identification and purification of novel growth factors important for growth and differentiation of human prostate epithelial

-34-

cells. These cells are particularly useful for such an application since they grow in serum-free media. Therefore, responses to growth factors can be studied in precisely defined growth media and any factors produced by the cells may be identified and purified without the complication of the presence of serum.

18. **Use of recombinant DNA expression vectors to produce proteins of interest:** For example, the gene encoding a protein of therapeutic value may be recombined with controlling DNA segments (i.e. containing a promoter with or without an enhancer sequence), transferred into the cell (e.g. by polybrene transection) and then the protein produced may be harvested from the culture supernatant or a cellular extract by routine procedures well known in the art.

19. **Characterization of cell surface antigens:** The cells are incubated with an antibody against the cell surface antigen of interest, and then reacted with a second antibody which is conjugated to a fluorescent dye. The cells are then evaluated using a fluorescence activated cell sorter to determine whether they are fluorescent and therefore possess the cell surface antigen.

20. **Cell-cell hybrid studies for identification of tumor suppressor activity (Stanbridge et al, Science 215:252-259 (1982)):** To determine whether immortalized non-malignant cell lines contain tumor suppressor genes, they are fused to malignant tumor cells. The presence of tumor suppressor genes in hybrid cells is indicated by loss of malignant properties, i.e., loss of *in vitro* characteristics of cancer cells, such as, density dependent inhibition of growth, growth in agar, stimulation of growth by autocrine secretion of growth factors and ability to form tumors in athymic nude mice.

21. **Identification of novel genes:** Including transforming genes in naturally occurring cancers, growth factor genes, oncogenes, tumor suppressor genes,

-35-

using standard molecular biological techniques (Davis et al., Methods in Molecular Biology, New York: Elsevier, pp. 167-189, (1986)) and techniques such as cDNA subtraction cloning and the like.

5 **22. Model for alternatives to animal testing:** There is
presently a great deal of concern about the use of
animals for testing products for human use. With the
upsurge of interest in the Animal Rights Movement,
considerable emphasis is being placed on the development
10 of cell culture models as alternatives to using animals
for testing. The drug and the cosmetic industry and
manufacturers of household and industrial chemicals are
interested in using cell culture models, especially
those derived from human cells, to test for human
15 toxicity of their products.

A kit for screening carcinogenic or
antineoplastic agents and for any other usage as
described herein supra, is easily assembled, comprising
the cell line(s) of the present invention. Other
20 components routinely found in such kits may also be
included with instructions for performing the test.

The cells of the present invention may be made
malignant by exposure to a virus, transfected with an
activated oncogene, radiation or to chemical carcinogens
25 including, for example, N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG) or N-methyl-N-nitrosourea (NMU),
tumor promoters such as and by promotion with 12-O-
tetradecanoylphorbol-13-acetate (TPA) or hormones. All
of this is well known to those skilled in the art.

30 The cell lines include cells of epithelial and
fibroblast origin. The epithelial cells include stem,
basal, intermediate and differentiated luminal cells.
The prostatic cells can be from various donors and cell
types.

-36-

5 An application which is co-pending with the present application by some of the inventors herein describes HPV immortalized cells. This invention is different than the present invention since a different virus was used.

 It is intended that the foregoing description be only illustrative of the present invention and that the present invention be limited only by the hereinafter appended claims.

-37-

WE CLAIM:

-1-

An immortalized human prostatic epithelial or fibroblast cell line and derivatives thereof, free of other cell lines in culture and containing DNA of adenovirus and simian virus as a hybrid virus.

-2-

The cell line of Claim 1 wherein the simian virus is simian virus 40 deposited as ATCC VR-239.

-3-

The cell line of Claim 1 wherein the adenovirus is adenovirus 12 deposited as ATCC VR-863.

-4-

The cell line of Claim 1 wherein the adenovirus is adenovirus 12 and the simian virus is simian virus 40 deposited as ATCC VR-863 and VR-239, respectively.

-5-

A cell line deposited as ATCC CRL 11611.

-6-

A method for producing an immortalized human prostatic epithelial or fibroblast cell line which comprises:

- 5 (a) providing non-malignant human prostatic epithelial or fibroblast cells; and
- (b) infecting the human prostatic epithelial cells with DNA adenovirus and simian virus to thereby immortalize the cells with the hybrid virus.

-38-

-7-

The method of Claim 6 wherein the simian virus is simian virus 40 deposited as ATCC VR-239.

-8-

The method of Claim 6 wherein the adenovirus is adenovirus 12 deposited as ATCC VR-863.

-9-

The method of Claim 6 wherein the adenovirus is adenovirus 12 and the simian virus is simian virus 40 deposited as ATCC VR-863 and VR-239, respectively.

-10-

The method of Claim 6 wherein the immortalized cell line is deposited as ATCC CRL 11611.

-11-

5 A kit for screening a carcinogenic, chemotherapeutic, chemopreventive, anti-invasive, anti-metastatic or anti-angiogenic agent comprising an immortalized human prostate epithelial cell line or derivatives thereof containing DNA of adenovirus and simian virus as a hybrid virus.

-12-

A kit according to Claim 11 wherein the immortalized cell line is immortalized using simian virus 40 as the simian virus deposited as ATCC VR-239 and adenovirus 12 deposited as ATCC VR-863.

-13-

A kit according to Claim 11 wherein the immortalized cell line is non-tumorigenic.

-39-

-14-

5 A kit according to Claim 11 wherein the immortalized cell line is made tumorigenic after additional transformation steps involving infection with oncogenic viruses, activation of oncogenes, transfection with activated oncogenes, loss of suppressor genes, or exposure to chemical carcinogens and promoters or radiation.

-15-

5 A method for testing carcinogenicity of an agent comprising culturing the cell line of Claim 1 with an agent suspected of being carcinogenic or exposing the cells to radiation, and determining formation of an abnormal cellular mass by said cell line, the formation of the abnormal cellular mass being indicative of carcinogenicity of said agent.

-16-

5 A method for testing antineoplastic activity of an agent comprising culturing the cell line of Claim 14 with a potential antineoplastic agent and determining growth of said cell line, a lack of growth of said cell line being indicative of antineoplastic potency of said agent.

-17-

The method of Claim 1 wherein the cells are made tumorigenic by the introduction of a cooperating, activated oncogene, such as, v-ras in the cells.

-18-

The method of Claim 14 wherein a normal tumor suppressor gene is introduced into the cell which results in a loss of tumorigenicity.

-40-

-19-

5 An immortalized human prostatic epithelial or fibroblast cell line or derivatives thereof of claim wherein the cell line has the phenotypic characteristics comprising; cytokeratins 8/18 positive, desmin negative, Factor VIII negative, contact inhibited, anchorage dependent, androgen responsive, plasminogen activator secretion normal, collagenase secretion normal, and is non-tumorigenic.

-20-

A method of determining carcinogenicity of an agent comprising:

- 5 a) culturing an immortalized human prostatic epithelial cell line of claim 1 with an agent suspected of being carcinogenic; and
- b) measuring a change in phenotypic characteristics of the cell line induced by the agent.

-21-

The method of Claim 20, wherein the phenotypic characteristic is increased urokinase expression, said increase being indicative of carcinogenicity or promoting activity of the agent.

-22-

5 The method of Claim 20, wherein the phenotypic characteristic is increased type IV collagenase expression, said increase being indicative of promoting activity of the agent or the agent having the ability to enhance tumor progression.

-41-

-23-

A method of detecting malignant human prostatic epithelial cells comprising:

a) obtaining human prostate epithelial cells, said cells suspected of being malignant; and

5 b) determining the activity of an enzyme produced by the cell in culture in comparison to the activity produced by normal human prostatic epithelial cells, a higher activity may be indicative of malignant cells.

-24-

A method of Claim 21 wherein the enzyme is urokinase.

-25-

A method of Claim 22 wherein the enzymes are type IV collagenases.

-26-

A method for conducting studies on cellular senescence and acquisition of immortality wherein the cell line of Claim 1 is used.

-27-

A method for conducting studies on the mechanisms involved in loss of tumor suppressor gene activity and the consequences of this loss resulting in cancer wherein the cell line of Claim 1 is used.

AMENDED CLAIMS

[received by the International Bureau on 26 September 1995 (26.09.95);
original claims 1,6,10-14 and 19 amended; new claims 28-33 added;
remaining claims unchanged (7 pages)]

-1-

5 An immortalized adult human normal prostatic
epithelial or fibroblast cell derived cell line free of
other cell lines and containing DNA of adenovirus and
simian virus as a hybrid virus, the cell line having the
identifying characteristics of the prostatic epithelial
or fibroblast cell without the hybrid virus in addition
to being immortalized by the hybrid virus.

-2-

The cell line of Claim 1 wherein the simian
virus is simian virus 40 deposited as ATCC VR-239.

-3-

The cell line of Claim 1 wherein the
adenovirus is adenovirus 12 deposited as ATCC VR-863.

-4-

The cell line of Claim 1 wherein the
adenovirus is adenovirus 12 and the simian virus is
simian virus 40 deposited as ATCC VR-863 and VR-239,
respectively.

-5-

A cell line deposited as ATCC CRL 11611.

-43-

-6-

A method for producing an immortalized adult human normal prostatic epithelial or fibroblast cell derived cell line which comprises:

- 5 (a) providing non-malignant human prostatic epithelial or fibroblast cells in a medium; and
- (b) infecting the human prostatic epithelial or fibroblast cells in the medium with DNA from adenovirus and simian virus as a hybrid virus to thereby
10 immortalize the cells with the hybrid virus to produce the cell line, wherein the cell line has the identifying characteristics of the prostatic epithelial or fibroblast cell without the hybrid virus in addition to being immortalized by the hybrid virus.

-7-

The method of Claim 6 wherein the simian virus is simian virus 40 deposited as ATCC VR-239.

-8-

The method of Claim 6 wherein the adenovirus is adenovirus 12 deposited as ATCC VR-863.

-9-

The method of Claim 6 wherein the adenovirus is adenovirus 12 and the simian virus is simian virus 40 deposited as ATCC VR-863 and VR-239, respectively.

-44-

-10-

The method of Claim 6 wherein the immortalized cell line deposited as ATCC CRL 11611.

-11-

5 A kit for screening a carcinogenic, chemotherapeutic, chemopreventive, anti-invasive, anti-metastatic or anti-angiogenic agent comprising an immortalized adult human prostatic epithelial cell derived cell line containing DNA of adenovirus and simian virus as a hybrid virus, the cell line having the identifying characteristics of the prostatic epithelial cell without the hybrid virus in addition to being immortalized by the hybrid virus.

-12-

The kit according to Claim 11 wherein the immortalized cell line is immortalized using simian virus 40 as the simian virus deposited as ATCC VR-239 and adenovirus 12 deposited as ATCC VR-863.

-13-

The kit according to Claim 11 wherein the immortalized cell line is non-tumorigenic.

-14-

5 The kit according to Claim 11 wherein the immortalized cell line is made tumorigenic after additional transformation by infection with oncogenic viruses, activation of oncogenes, transfection with activated oncogenes, loss of suppressor genes, or chemical exposure or radiation.

AMENDED SHEET (ARTICLE 19)

-45-

-15-

5 A method for testing carcinogenicity of an agent comprising culturing the cell line of Claim 1 with an agent suspected of being carcinogenic or exposing the cells to radiation, and determining formation of an abnormal cellular mass by said cell line, the formation of the abnormal cellular mass being indicative of carcinogenicity of said agent.

-16-

5 A method for testing antineoplastic activity of an agent comprising culturing the cell line of Claim 14 with a potential antineoplastic agent and determining growth of said cell line, a lack of growth of said cell line being indicative of antineoplastic potency of said agent.

-17-

The method of Claim 1 wherein the cells are made tumorigenic by the introduction of a cooperating, activated oncogene, such as, v-ras in the cells.

-18-

The method of Claim 14 wherein a normal tumor suppressor gene is introduced into the cell which results in a loss of tumorigenicity.

-19-

5 An immortalized human prostatic epithelial cell line or derivatives thereof wherein the cell line has the phenotypic characteristics comprising; cytokeratins 8/18 positive, desmin negative, Factor VIII negative, contact inhibited, anchorage dependent, androgen responsive, plasminogen activator secretion normal, collagenase secretion normal, and is non-tumorigenic, produces prostate specific antigen and contains a hybrid virus of adenovirus and simian virus.

-20-

A method of determining carcinogenicity of an agent comprising:

- 5 a) culturing an immortalized human prostatic epithelial cell line of claim 1 with an agent suspected of being carcinogenic; and
- b) measuring a change in phenotypic characteristics of the cell line induced by the agent.

-21-

The method of Claim 20, wherein the phenotypic characteristic is increased urokinase expression, said increase being indicative of carcinogenicity or promoting activity of the agent.

-22-

5 The method of Claim 20, wherein the phenotypic characteristic is increased type IV collagenase expression, said increase being indicative of promoting activity of the agent or the agent having the ability to enhance tumor progression.

-47-

-23-

A method of detecting malignant human prostatic epithelial cells comprising:

- a) obtaining human prostate epithelial cells, said cells suspected of being malignant; and
- 5 b) determining the activity of an enzyme produced by the cell in culture in comparison to the activity produced by normal human prostatic epithelial cells, a higher activity may be indicative of malignant cells.

-24-

A method of Claim 21 wherein the enzyme is urokinase.

-25-

A method of Claim 22 wherein the enzymes are type IV collagenases.

-26-

A method for conducting studies on cellular senescence and acquisition of immortality wherein the cell line of Claim 1 is used.

-27-

A method for conducting studies on the mechanisms involved in loss of tumor suppressor gene activity and the consequences of this loss resulting in cancer wherein the cell line of Claim 1 is used.

-48-

-28-

The cell line of Claim 19 wherein the simian virus is simian virus 40 deposited as ATCC VR-239 and the adenovirus is adenovirus 12 deposited as ATCC VR-863.

-29-

The method of Claim 6 wherein after the infecting in step (b) the cell line is subjected to multiple cloning to select a non-virus producing cell line in a serum free, chemically defined medium.

-30-

The method of Claim 29 wherein the medium contains pituitary extract and epidermal growth factor.

-31-

The cell line of Claim 1 which produces prostate specific antigen.

-32-

The kit of Claim 11 wherein the cell line produces prostate specific antigen.

-33-

The method of Claim 6 wherein the cell line produces prostate specific antigen.



FIG. 1A




FIG. 1B

2/5

FIG. 2





FIG. 3



3/5




FIG. 4




FIG. 5

4/5



FIG. 6A




FIG. 6B

5/5




FIG. 6C




FIG. 6D

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US95/05389

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Journal of Virology, Volume 61, no. 9, issued September 1987, Gish et al., "Simian Virus 40-transformed Human Cells That Express Large T Antigens Defective for Viral DNA Replication", pages 2864-2876, see entire document.	1-27
Y	Proceedings of the National Academy of Sciences, volume 55, issued 1966, Schell et al., "Potentiation of oncogenicity of adenovirus type 12 grown in African green monkey kidney cell cultures reinfected with SV40 virus: persistence of both T antigens in the tumors and evidence for possible hybridization", pages 81-88, see entire document.	1-27



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A		document defining the general state of the art which is not considered to be of particular relevance
* E		earlier document published on or after the international filing date
* L		document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* O		document referring to an oral disclosure, use, exhibition or other means
* P		document published prior to the international filing date but later than the priority date claimed
	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
	* Z	document member of the same patent family

Date of the actual completion of the international search

08 JULY 1995

Date of mailing of the international search report

04 AUG 1995

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JAMES KETTER

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/05389

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Science, Volume 232, issued 18 April 1986, Rhim et al., "Neoplastic Conversion of Human Keratinocytes by Adenovirus 12-SV40 Virus and Chemical Carcinogens", pages 385-388, see entire document.	1-27
Y	Cancer Research, Volume 48, issued April 1988, Reddel et al., "Transformation of Human Bronchial epithelial Cells by Infection with SV40 or Adenovirus-12 SV40 hybrid Virus, or Transfection via Strontium Phosphate Coprecipitation with a Plasmid Containing SV40 Early Region Genes", pages 1904-1909, see entire document.	1-27
Y	Cancer Research (Supplemental), Volume 50, issued 01 September 1990, Rhim et al., "Evidence for the Multistep nature of <i>in Vitro</i> Human Epithelial Cell Carcinogenesis", pages 5653s-5657s, see entire document.	1-27
Y	The Journal of Urology, Volume 143, issued September 1991, Cussenot et al., "Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene", pages 881-886, see entire document.	1-27
Y	Anticancer Research, Volume 13, issued 1993, Koutsilieris, "Osteoblastic Metastasis in Advanced Prostate Cancer", pages 443-449, see entire document.	21, 24
Y	Cancer Research, Volume 48, issued 15 November 1988, Wang et al., "Blocking of collagenase Secretion by Estramustine during <i>in Vitro</i> Tumor Cell Invasion", pages 6262-6271, see entire document.	22, 25

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/05389

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6): C12N 5/10; 15/64; C12Q 1/68

A. CLASSIFICATION OF SUBJECT MATTER:
US CL : 435/6, 172.3, 240.2

B. FIELDS SEARCHED
Minimum documentation searched
Classification System: U.S. 435/6, 172.3, 240.2

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

APS, MEDLINE EXPRESS